Updated:
The Firmament Group
Firmament is an architect of versatile growth capital solutions to small- and medium-sized enterprises (SMEs) globally. It provides control equity, minority...
The Firmament Group
Firmament is an architect of versatile growth capital solutions to small- and medium-sized enterprises (SMEs) globally. It provides control equity, minority equity and growth debt capital to lower-middle market businesses primarily in Technology, Healthcare and the Environment. It also acts as a financing source providing customized debt financings to middle market businesses in sponsor and non-sponsor credit markets.
General information
Firm type
Generalist
Year founded
2013
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Greenoaks Capital
Founding partner / anchor LP
Stone Point Capital
Founding partner / anchor LP
Sector focus
Frequently asked questions
How does The Firmament Group source deals?
Firmament sources through a network of regional investment banks, independent sponsors, and operating executives focused on lower-middle-market companies. The firm's anchor LPs, Stone Point Capital and Greenoaks Capital, also provide origination referrals from their respective financial-services and technology ecosystems. Firmament emphasizes relationships with founder-owners who are not running a formal sale process.
Does Firmament co-invest alongside other external managers?
Firmament has not publicized a formal external co-investor program. The firm structures deals primarily with its own balance sheet capital from anchor sponsors. On occasion, it has participated alongside independent sponsors and family offices in club-style transactions, but this is opportunistic rather than programmatic.
Which sectors does Firmament explicitly avoid?
Firmament does not publicly list explicit sector exclusions. However, given its lower-middle-market focus and the sponsor backgrounds of Stone Point (insurance and financial services consolidation) and Greenoaks (technology), the firm has historically avoided capital-intensive heavy manufacturing, upstream energy, and biotech/pharma therapeutics where clinical risk profiles are incompatible with its structured credit orientation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: